Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

DISEASE CHARACTERISTICS: * Recipient of an allogeneic stem cell transplantation * Cytomegalovirus (CMV)-seropositive and meeting 1 of the following criteria: * Patient has a history of CMV antigenemia for ≥ 2 weeks * CMV DNA levels ≥ 600 copies/mcg of DNA despite antiviral therapy targeting CMV (e.g., ganciclovir or foscarnet) * No ongoing graft-vs-host disease * Has donor available for peripheral blood mononuclear cell collection (for cytotoxic T lymphocytes production), meeting either of the following criteria: * CMV-seropositive donor (≥ 2 years of age) * CMV-seronegative related donor (≥ 18 years of age) who consents to receive the CMV vaccine PATIENT CHARACTERISTICS: * ECOG performance status (PS) 0-3 OR Lansky PS 50-100% (for patients \< 16 years of age) * Bilirubin \< 2.0 mg/dL * AST and ALT \< 2.5 times normal * Creatinine clearance ≥ 30 mL/min * Pulse oximetry ≥ 94% on no more than 40% oxygen by face mask * Not moribund * No patients expected to survive ≤ 1 month after the T-cell infusion due to cardiac, pulmonary, renal, hepatic, or neurologic dysfunction PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Must be on ≤ 1 mg/kg/day of prednisone or its equivalent at the time of study CTL infusion